[1] [1] Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J]. Circulation, 2019, 140(8):e382-e482.

[2] [2] Scott B, Hameed A, Knox R. Bradycardia and syncope: the case of the torted gallbladder[J]. ANZ J Surg, 2021, 91(1-2):E50-E51.

[3] [3] Greene SC, Halmer T, Carey JM, et al. Theophylline toxicity: An old poisoning for a new generation of physicians[J]. Turk J Emerg Med, 2018, 18(1):37-39.

[4] [4] Zhang XJ, Tan H, Shi ZF, et al. Growth differentiation factor 11 is involved in isoproterenol induced heart failure[J]. Mol Med Rep, 2019, 19(5):4109-4118.

[5] [5] Prez-Riera AR, Barbosa-Barros R, Daminello-Raimundo R, et al. Current aspects of the basic concepts of the electrophysiology of the sinoatrial node[J]. J Electrocardiol, 2019, 57:112-118.

[6] [6] Lang D, Glukhov AV. Cellular and molecular mechanisms of functional hierarchy of pacemaker clusters in the sinoatrial node: new insights into sick sinus syndrome[J]. J Cardiovasc Dev Dis, 2021, 8(4):43.

[7] [7] Kozasa Y, Nakashima N, Ito M, et al. HCN4 pacemaker channels attenuate the parasympathetic response and stabilize the spontaneous firing of the sinoatrial node[J]. J Physiol, 2018, 596(5):809-825.

[8] [8] Wilde AAM, Amin AS. Clinical spectrum of SCN5A mutations: long QT syndrome, brugada syndrome, and cardiomyopathy[J]. JACC Clin Electrophysiol, 2018, 4(5):569-579.

[9] [9] Su S, Sun J, Wang Y, et al. Cardiac hERG K+ channel as safety and pharmacological target[J]. Handb Exp Pharmacol, 2021, 267:139-166.

[10] [10] Kurakami K, Norota I, Nasu F, et al. KCNQ1 is internalized by activation of 1 adrenergic receptors[J]. Biochem Pharmacol, 2019, 169:113628.

[11] [11] Corponi F, Fabbri C, Boriani G, et al. Corrected QT interval prolongation in psychopharmacological treatment and its modulation by genetic variation[J]. Neuropsychobiology, 2019, 77(2):67-72.

[12] [12] Yang Z, Ma Y, Huang J, et al. Digenic heterozygous mutations of KCNH2 and SCN5A induced young and early-onset long QT syndrome and sinoatrial node dysfunction[J]. Ann Noninvasive Electrocardiol, 2022, 27(1):e12889.

[13] [13] Marchant JL, Farrell AP. Membrane and calcium clock mechanisms contribute variably as a function of temperature to setting cardiac pacemaker rate in zebrafish Danio rerio[J]. J Fish Biol, 2019, 95(5):1265-1274.

[14] [14] Kim MS, Maltsev AV, Monfredi O, et al. Heterogeneity of calcium clock functions in dormant, dysrhythmically and rhythmically firing single pacemaker cells isolated from SA node[J]. Cell Calcium, 2018, 74:168-179.

[15] [15] Kaese S, Bgeholz N, Pauls P, et al. Increased sodium/calcium exchanger activity enhances beta-adrenergic-mediated increase in heart rate: Whole-heart study in a homozygous sodium/calcium exchanger overexpressor mouse model[J]. Heart Rhythm, 2017, 14(8):1247-1253.

[16] [16] Haverinen J, Hassinen M, Dash SN, et al. Expression of calcium channel transcripts in the zebrafish heart: dominance of T-type channels[J]. J Exp Biol, 2018, 221(Pt 10):581-595.

[17] [17] Lazzerini PE, Capecchi PL, Laghi-Pasini F, et al. Autoimmune channelopathies as a novel mechanism in cardiac arrhythmias[J]. Nat Rev Cardiol, 2017, 14(9):521-535.

[18] [18] Baudot M, Torre E, Bidaud I, et al. Concomitant genetic ablation of L-type Cav1.3 (1D) and T-type Cav3.1 (1G) Ca2+ channels disrupts heart automaticity[J]. Sci Rep, 2020, 10(1):18906.

[19] [19] Saito Y, Nakamura K, Nishi N, et al. TRPM4 mutation in patients with ventricular noncompaction and cardiac conduction disease[J]. Circ Genom Precis Med, 2018, 11(5):e002103.

[20] [20] Bidaud I, Chong ACY, Carcouet A, et al. Inhibition of G protein-gated K+ channels by tertiapin-Q rescues sinus node dysfunction and atrioventricular conduction in mouse models of primary bradycardia[J]. Sci Rep, 2020, 10(1):9835.

[21] [21] Balducci V, Credi C, Sacconi L, et al. The HCN channel as a pharmacological target: Why, where, and how to block it[J]. Prog Biophys Mol Biol, 2021, 166:173-181.

[22] [22] Alvarez-Baron CP, Klenchin VA, Chanda B. Minimal molecular determinants of isoform-specific differences in efficacy in the HCN channel family[J]. J Gen Physiol, 2018, 150(8):1203-1213.

[23] [23] Hennis K, Rtzer RD, Piantoni C, et al. Speeding Up the heart? Traditional and new perspectives on HCN4 function[J]. Front Physiol, 2021, 12:669029.

[24] [24] Li Y, Wang K, Li Q, et al. Biological pacemaker: from biological experiments to computational simulation[J]. J Zhejiang Univ Sci B, 2020, 21(7):524-536.

[25] [25] Laish-Farkash A, Glikson M, Brass D, et al. A novel mutation in the HCN4 gene causes symptomatic sinus bradycardia in Moroccan Jews[J]. J Cardiovasc Electrophysiol, 2010, 21(12):1365-1372.

[26] [26] Li Y, Zhang X, Zhang C, et al. Increasing T-type calcium channel activity by -adrenergic stimulation contributes to -adrenergic regulation of heart rates[J]. J Physiol, 2018, 596(7):1137-1151.

[27] [27] Armenian S, Bhatia S. Predicting and preventing anthracycline-related cardiotoxicity[J]. Am Soc Clin Oncol Educ Book, 2018, 38:3-12.

[28] [28] Herradn E, Gonzlez C, Uranga JA, et al. Characterization of cardiovascular alterations Induced by different chronic cisplatin treatments[J]. Front Pharmacol, 2017, 8:196.

[29] [29] Ye JZ, Hansen FB, Mills RW, et al. Oncotherapeutic protein kinase inhibitors associated with pro-arrhythmic liability[J]. JACC Cardio Oncol, 2021, 3(1):88-97.

[30] [30] Jensen PN, Gronroos NN, Chen LY, et al. Incidence of and risk factors for sick sinus syndrome in the general population[J]. J Amer Coll Cardiol, 2014, 64(6):531-538.

[31] [31] John RM, Kumar S. Sinus node and atrial arrhythmias[J]. Circulation, 2016, 133(19):1892-1900.

[32] [32] Miyazawa K, Miyazono K. Regulation of TGF- family signaling by inhibitory smads[J]. Cold Spring Harb Perspect Biol, 2017, 9(3):a022095.

[33] [33] Hanna A, Humeres C, Frangogiannis NG. The role of Smad signaling cascades in cardiac fibrosis[J]. Cell Signal, 2021, 77:109826.

[34] [34] Monti CB, Codari M, De Cecco CN, et al. Novel imaging biomarkers: epicardial adipose tissue evaluation[J]. Br J Radiol, 2020, 93(1113):20190770.

[35] [35] Hashem SI, Lam ML, Mihardja SS, et al. Shox2 regulates the pacemaker gene program in embryoid bodies[J]. Stem Cells Dev, 2013, 22(21):2915-2926.

[36] [36] Liu H, Espinoza-Lewis RA, Chen C, et al. The role of Shox2 in SAN development and function[J]. Pediatr Cardiol, 2012, 33(6):882-889.

[37] [37] Koenig SN, Mohler PJ. The evolving role of ankyrin-B in cardiovascular disease[J]. Heart Rhythm, 2017, 14(12):1884-1889.

[39] [39] Bebawi E, Jouni SS, Tessier AA, et al. A metoprolol-terbinafine combination induced bradycardia[J]. Eur J Drug Metab Pharmacokinet, 2015, 40(3):295-299.

[41] [41] Zhu G, Ueda K, Hashimoto M, et al. The mitochondrial regulator PGC1 is induced by cGMP-PKG signaling and mediates the protective effects of phosphodiesterase 5 inhibition in heart failure[J]. FEBS Lett, 2022, 596(1):17-28.

[47] [47] Zhang J, Huang C. A new combination of transcription factors increases the harvesting efficiency of pacemaker like cells[J]. Mol Med Report, 2019, 19(5):3584-3592.